UBS Group AG Buys 98,207 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

UBS Group AG raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 199.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 147,384 shares of the biopharmaceutical company’s stock after purchasing an additional 98,207 shares during the period. UBS Group AG owned 0.11% of Halozyme Therapeutics worth $8,386,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Cullen Frost Bankers Inc. bought a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $40,000. Harvest Fund Management Co. Ltd bought a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $57,000. Almanack Investment Partners LLC. bought a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $55,000. IFP Advisors Inc lifted its holdings in shares of Halozyme Therapeutics by 87.9% in the 3rd quarter. IFP Advisors Inc now owns 1,717 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 803 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $156,000. Institutional investors own 96.32% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $33.45 on Thursday. The firm has a market cap of $4.40 billion, a PE ratio of 25.53, a price-to-earnings-growth ratio of 0.55 and a beta of 1.21. The firm’s 50 day simple moving average is $34.55 and its 200-day simple moving average is $46.07. Halozyme Therapeutics, Inc. has a one year low of $29.85 and a one year high of $59.46. The company has a debt-to-equity ratio of 22.69, a quick ratio of 5.52 and a current ratio of 6.69.

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last issued its earnings results on Tuesday, February 21st. The biopharmaceutical company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.01. The business had revenue of $181.50 million for the quarter, compared to analyst estimates of $186.07 million. Halozyme Therapeutics had a net margin of 25.76% and a return on equity of 184.32%. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 2.44 EPS for the current year.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Monday, February 27th. The shares were sold at an average price of $49.55, for a total transaction of $495,500.00. Following the transaction, the senior vice president now directly owns 138,927 shares in the company, valued at $6,883,832.85. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 50,000 shares of company stock worth $2,214,600. Corporate insiders own 2.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. SVB Leerink downgraded shares of Halozyme Therapeutics from an “outperform” rating to a “market perform” rating and set a $42.00 price target for the company. in a report on Thursday, March 16th. JPMorgan Chase & Co. reduced their price objective on shares of Halozyme Therapeutics from $54.00 to $52.00 and set an “overweight” rating on the stock in a research report on Thursday, February 23rd. Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $65.00 to $64.00 and set an “overweight” rating on the stock in a research report on Monday, March 6th. JMP Securities reissued a “market outperform” rating and issued a $66.00 price objective (up from $62.00) on shares of Halozyme Therapeutics in a research report on Wednesday, February 22nd. Finally, Piper Sandler raised shares of Halozyme Therapeutics from a “neutral” rating to an “overweight” rating and set a $46.00 price objective on the stock in a research report on Wednesday, May 10th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $55.30.

Halozyme Therapeutics Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.